NEW YORK (GenomeWeb News) – NuMedii announced today that it has raised $3.5 million in a Series A funding round led by Claremont Creek Ventures and Lightspeed Venture Partners with participation from Life Science Angels and others.

NuMedii said that it will use the funding to further develop its proprietary technology and prepare its first three internal drug development programs for clinical testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.